Telomir Pharmaceuticals (TELO) Projected to Post Quarterly Earnings on Wednesday

Telomir Pharmaceuticals (NASDAQ:TELO) will likely be issuing its results after the market closes on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.07) per share for the quarter.

Telomir Pharmaceuticals (NASDAQ:TELO) last released its quarterly earnings results on Tuesday, March 17th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.01.

Telomir Pharmaceuticals Trading Up 0.8%

NASDAQ:TELO opened at $1.33 on Wednesday. The stock has a market cap of $45.73 million, a P/E ratio of -4.03 and a beta of -0.21. The stock’s 50-day moving average is $1.32 and its 200-day moving average is $1.34. Telomir Pharmaceuticals has a 1-year low of $1.05 and a 1-year high of $3.10.

Institutional Trading of Telomir Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in TELO. Bank of America Corp DE boosted its holdings in Telomir Pharmaceuticals by 283.9% in the fourth quarter. Bank of America Corp DE now owns 14,713 shares of the company’s stock valued at $61,000 after acquiring an additional 10,880 shares during the last quarter. Marshall Wace LLP acquired a new position in Telomir Pharmaceuticals in the second quarter valued at approximately $95,000. Qube Research & Technologies Ltd acquired a new position in Telomir Pharmaceuticals in the second quarter valued at approximately $33,000. Jane Street Group LLC acquired a new position in Telomir Pharmaceuticals in the second quarter valued at approximately $62,000. Finally, Raymond James Financial Inc. lifted its stake in Telomir Pharmaceuticals by 4,101.9% in the third quarter. Raymond James Financial Inc. now owns 75,340 shares of the company’s stock valued at $105,000 after buying an additional 73,547 shares during the period.

Analysts Set New Price Targets

Several analysts recently commented on TELO shares. Wall Street Zen upgraded Telomir Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, February 21st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a report on Tuesday, April 21st. Zacks Research upgraded Telomir Pharmaceuticals to a “hold” rating in a report on Wednesday, March 18th. Finally, Rodman & Renshaw started coverage on Telomir Pharmaceuticals in a report on Tuesday, January 13th. They issued a “buy” rating on the stock. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold”.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc (NASDAQ: TELO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company’s lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling.